29 citations
,
January 2016 in “CNS drugs” Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.
16 citations
,
April 2006 in “Pediatrics International” High-dose mizoribine effectively controls symptoms in adolescents with lupus while reducing steroid use, with manageable side effects.
6 citations
,
August 2022 in “Dermatologic therapy” PRP therapy can temporarily grow hair in CCCA patients but isn't a permanent cure.
22 citations
,
January 2013 in “Journal of The American Academy of Dermatology” Birth control pills can help manage acne, but dermatologists should know their skin-related side effects, especially when prescribing drugs that can harm unborn babies.
2 citations
,
January 2017 in “Annals of Dermatology” Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.
May 2025 in “The Journal of Rheumatology” Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.
17 citations
,
January 2015 in “JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH” Cronkhite-Canada syndrome is a rare, non-inherited condition causing various symptoms like polyps, hair loss, and weight loss.
January 2024 in “Pharmaceutical journal/The pharmaceutical journal” Ritlecitinib can help about 14,000 people with severe hair loss.
29 citations
,
February 2022 in “Frontiers in Cell and Developmental Biology” Improving CRISPR/Cas systems can make gene editing more efficient and precise.
42 citations
,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.
April 2024 in “JEADV clinical practice” Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
1 citations
,
August 2024 in “British Journal of Dermatology” Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.
17 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
22 citations
,
June 2002 in “Journal of Medicinal Chemistry” Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.
January 2025 in “Journal of Carcinogenesis” Inflammation is a key factor in heart disease and targeting it can reduce heart problems.
2 citations
,
February 2018 in “International Research Journal of Pharmacy” Eclipta alba leaf alkaloids may help treat HIV by inhibiting the virus's activity.
1 citations
,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
May 2025 in “Immunotherapy” Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.
350 citations
,
June 1989 in “The American Journal of Medicine” Itraconazole is potentially effective for treating invasive aspergillosis, but more research is needed.
1 citations
,
September 2023 in “Frontiers in Genetics” A heterozygous mutation in HTRA1 can cause severe CARASIL symptoms.
January 2026 in “Frontiers in Pharmacology” Cedrol may help treat inflammatory bowel disease by improving gut health and function.
6 citations
,
March 2007 in “BioTechniques” PCR genotyping in cre-loxP mice can be inaccurate due to unintended gene deletions in non-target tissues.
88 citations
,
July 2009 in “Experimental and Clinical Endocrinology & Diabetes” May 2026 in “Chemical Engineering Journal”
Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.
1 citations
,
September 1981 in “PubMed” Cyproterone acetate effectively treats virilized women, especially under 35, despite some side effects.
August 2011 in “Der Urologe” 5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
70 citations
,
July 2020 in “Pharmacological Reports” Cepharanthine, a Japanese hair loss drug, shows promise as a COVID-19 treatment but needs more testing.